Abstract:A recombinant subunit vaccine (Shingrix®) was recently licensed for use against herpes zoster. This vaccine is based on glycoprotein E (gE) of varicella zoster virus (VZV), the most abundantly expressed protein of VZV, harboring sites for N- and O-linked glycosylation. The subunit vaccine elicits stronger virus-specific CD4+ T cell response as well as antibody B cell response to gE, compared to the currently used live attenuated vaccine (Zostavax®). This situation is at variance with the current notion since a live vaccine, causing an active virus infection, should be far more efficient than a subunit vaccine based on only one single viral glycoprotein. We previously found gE to be heavily glycosylated, not least by numerous clustered O-linked glycans, when it was produced in human fibroblasts. However, in contrast to Zostavax®, which is produced in fibroblasts, the recombinant gE of Shingrix® is expressed in Chinese hamster ovary (CHO) cells. Hence, the glycan occupancy and glycan structures of gE may differ considerably between the two vaccine types. Here, we aimed at (i) defining the glycan structures and positions of recombinant gE and (ii) identifying possible features of the recombinant gE O-glycosylation pattern contributing to the vaccine efficacy of Shingrix®. Firstly, recombinant gE produced in CHO cells (“Shingrix situation”) is more scarcely decorated by O-linked glycans than gE from human fibroblasts (“Zostavax situation”), with respect to glycan site occupancy. Secondly, screening of immunodominant B cell epitopes of gE, using a synthetic peptide library against serum samples from VZV-seropositive individuals, revealed that the O-linked glycan signature promoted binding of IgG antibodies via a decreased number of interfering O-linked glycans, but also via specific O-linked glycans enhancing antibody binding. These findings may, in part, explain the higher protective efficacy of Shingrix®, and can also be of relevance for development of subunit vaccines to other enveloped viruses.

Chemical Synthesis Creates Single Glycoforms of the Ectodomain of Herpes Simplex Virus-1 Glycoprotein D

Expression of Recombinant Herpes Simplex Virus Type 2 Glycoprotein D by High-Density Cell Culture of Spodoptera Frugiperda

Synthesis and Verification of Herpes Simplex Virus Envelope Glycoprotein Gc

High-level expression of glycoprotein D by a dominant-negative HSV-1 virus augments its efficacy as a vaccine against HSV-1 infection.

Localization and synthesis of an antigenic determinant of herpes simplex virus glycoprotein D that stimulates the production of neutralizing antibody

Prokaryotic Expression and Purification of Major Epitopes Domain of Herpes Simplex Virus Type 1 Glycoprotein D

Construction and characterization of a synthesized herpes simplex virus H129-Syn-G2

Two Step Culture for Production of Recombinant Herpes Simplex Virus Type 2 Glycoprotein D in Immobilized Spodoptera Frugiperda Cells

Integrating pan-genome and reverse vaccinology to design multi-epitope vaccine against Herpes simplex virus type-1

Evaluation of HSV-2 gE Binding to IgG-Fc and Application for Vaccine Development

Targeting herpesvirus entry complex and fusogen glycoproteins with prophylactic and therapeutic agents

Binding Of Herpes Simplex Virus Glycoprotein D To Nectin-1 Exploits Host Cell Adhesion

Two distinct trimeric conformations of natively membrane-anchored full-length herpes simplex virus 1 glycoprotein B

Computational design of prefusion-stabilized Herpesvirus gB trimers

Induction of Rod-Shaped Structures by Herpes Simplex Virus Glycoprotein I

Structures of the Varicella Zoster Virus Glycoprotein E and Epitope Mapping of Vaccine-Elicited Antibodies

Involvement of viral glycoprotein gC‐1 in expression of the selectin ligand sialyl‐Lewis X induced after infection with herpes simplex virus type 1

Mucin‐Inspired Polymeric Fibers for Herpes Simplex Virus Type 1 Inhibition

Efficient Strategy for Synthesizing Vector-Free and Oncolytic Herpes Simplex Type 1 Viruses

Recombinant Glycoprotein E of Varicella Zoster Virus Contains Glycan-Peptide Motifs That Modulate B Cell Epitopes into Discrete Immunological Signatures

Herpes Simplex Virus 1 Envelope Glycoprotein C Shields Glycoprotein D to Protect Virions from Entry-Blocking Antibodies